MX2010011780A - Condom with localized active agent. - Google Patents
Condom with localized active agent.Info
- Publication number
- MX2010011780A MX2010011780A MX2010011780A MX2010011780A MX2010011780A MX 2010011780 A MX2010011780 A MX 2010011780A MX 2010011780 A MX2010011780 A MX 2010011780A MX 2010011780 A MX2010011780 A MX 2010011780A MX 2010011780 A MX2010011780 A MX 2010011780A
- Authority
- MX
- Mexico
- Prior art keywords
- condom
- wax
- accordance
- reivi
- account
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 10
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 10
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 229940124549 vasodilator Drugs 0.000 claims abstract description 7
- 239000003071 vasodilator agent Substances 0.000 claims abstract description 7
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002639 sildenafil citrate Drugs 0.000 claims abstract description 4
- 238000002844 melting Methods 0.000 claims description 26
- 230000008018 melting Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 19
- 239000004615 ingredient Substances 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 niacin compound Chemical class 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 229920001971 elastomer Polymers 0.000 claims description 4
- 239000000806 elastomer Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- 244000043261 Hevea brasiliensis Species 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229920003052 natural elastomer Polymers 0.000 claims 1
- 229920001194 natural rubber Polymers 0.000 claims 1
- 229920003051 synthetic elastomer Polymers 0.000 claims 1
- 229940087419 nonoxynol-9 Drugs 0.000 abstract description 10
- 229920004918 nonoxynol-9 Polymers 0.000 abstract description 10
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 abstract description 10
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 abstract description 8
- 239000011324 bead Substances 0.000 abstract description 7
- 229960005274 benzocaine Drugs 0.000 abstract description 4
- 239000003975 dentin desensitizing agent Substances 0.000 abstract description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000006 Nitroglycerin Substances 0.000 abstract description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 abstract description 2
- 239000001993 wax Substances 0.000 description 35
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 4
- 239000000934 spermatocidal agent Substances 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920006173 natural rubber latex Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 241001135931 Anolis Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001257 erectogenic effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
- A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Provided are condoms and methods of making and using the same, the condoms having an elastomeric layer and a low melt wax bead which comprises an active ingredient mixed therein, wherein the bead is affixed on the interior surface of the elastomeric layer in the tip of the condom. Active ingredients can include spermicides such as nonoxynol-9 and vasodilators such as niacin, sildenafil citrate, and nitroglycerin and male desensitizing agents such as benzocaine. The bead can comprise a natural wax in combination with polyethylene glycol or it can be a polyethylene glycol-based wax. The exterior surface of the elastomeric layer is substantially free of the active ingredient.
Description
CONDOM WITH LOCALIZED ACTIVE AGENT
FIELD OF THE INVENTION
The embodiments of the present invention with condoms having an ingredient at the closed end of a specifically provided condoms having solubilized or mixed active ingredients or fine water-soluble fin within a melting point count. The ingredients, for example, liquid xinol-9 and other spermicides, as well as oglycerin, and sildenafil citrate dilators.
BACKGROUND OF THE INVENTION
Condoms and other prophylactics and dis
latex hood of a condom, as well as in an e the main sheath of the condom and a membrane. The packaging of Mallette, in addition, in rmicide to prevent dehydration of the U.S. patent. No. 4795425 (Pugh), spermicide is described, where a first dose is semisolid stado at the closed end of the cond nda dose is external surface of semisolid c S is presented as a spermicidal cream or anole is mixed with types of Polyethylene include Carbowax 400, which is not a wax environmental environment, and Carbowax 3350, which is a solid fusion material in the range of 54 ° C to 57 ° C which said cream or ointment has a 1-point range of 113-127 ° F. (45-53 ° C).
Spermicides such as nonoxynol-9; without emba
sexual anointing Topical application of therapeutics as vasodilators is an option. In Nos. 4829991 (Boeck) and p), condoms can be used for therapeutic purposes such as vasodilatatogenic compounds. In Kemp's work, a computer is immobilized at the closed end of the use of a support solvent, in the presence of a film-forming agent, which is often leaving the erectome compound to be finely divided or as a film layer. (or composition) Kemp's erectógeno is a condom lubricant. A composition comprises an erectono di elto compound in a carrier gel comprising a thickening agent. The desired thickeners depend
No. 086403 (Harrison), a condom has a lubricant bearing having a viscosity relayed and containing such a male desensitizing agent on the inner surface of the composition having a viscosity on the outer surface.
Glide particles may be used on elastomeric articles for placement or blocking, as described in, eg, U.S. No. 5405666 (Brindle); 6075081 (Nile); kel). Said use of wax; however, no localized portion of an active ingredient.
Therefore, there is a need for proactive agents with active agents in them to reduce the irritation of the membranes by diluting the agents released.
SUMMARY OF THE INVENTION
Condoms and fabrication methods are provided, condoms having a lastomer and a low-point wax bead comprises an active ingredient blended in and the bead is placed on the elastomeric interi surface at the tip of the condom. In a tundish, a condom comprises a low melting point elastomeric wax layer which xinol-9 is blended therein. Another embodiment of a desensitizing agent for man me counts, for example, benzocaine, dibucaine, l-acaine, and salts and derivatives of the same can comprise a wax based on p ol of selected molecular weight having an ion in the range from 25 ° C to 40 ° C. Alternative
ato ele sildenafil benzocaine.
In one aspect, methods are provided for billing a condom, the method comprising arranging a fused solution of a low-wax containing an active ingredient; pro ondón; drop an account of the inner fundial solution and on the tip of the condom; allowed to reach room temperature and leave solid so that the count is located at the top and at the tip of the condom; and packing of the co-providing molten solution can include the low melting point wax and active element having a low melting point melting point with the low-melting wax to form a substantially melted solution. Alternatively or additionally, said p
r a melting point in the range of 25 ° C to 100 μg of polyethylene glycol with a weight calculated to have a melting point at 40 ° C, where the bead is placed in the upper part of the elastomer layer at the tip of the onde the outer surface of the elasto layer substantially free of nonoxynol-9.
Additional aspects include the method of directing an erectogenic compound within the condom region, methods comprising procuron comprising an elastomeric layer and a low melting point comprising no side therein, the count comprising a wax ficada to have a melting point in the inte 40 C and an appropriate polyethylene glycol polymer to have a melting point
An active ingredient via a condom can be obtained from the active ingredient by using a suitable eye count on the tip of the condom on top of it. In this way, the active ingredient poured into a diluted form, even more effective, par tiation. In addition, localization of the condom ingredient reduces the exposure of the active ingredient to the environment. The use of a low-level wax, for example, allows the substantially uniform active ingredient in the account to further assist in the ingredient's diet.
In a first aspect, cond is provided in an elastomeric layer and a d-layer comprising a mixed active ingredient, wherein the count is located in the s
When manipulating, the minute amounts of active substance in the condom can pour on the outside surface. For the present invention, the active ingredients n located intentionally on the top are considered insignificant.
The reference to "low melting point" is aterial, as a wax or other suitable carrier, crushes, and / or melts in the presence of oral, which is about 37 ° C. In a modal it softens in the presence of body heat The ingredient ac or more embodiments, the wax or other carrier is substantially exposed in the range of 25 ° C-40 ° C.
One modality states that the ingredient renders a spermicide. In a specific modality
It is clear that the vasodilator comprises a component. A niacin component includes niacin acid as nicotinic acid), nicotinamide, nicotio (niacin methyl ester), derivatives of the inations thereof.
The terms "erectóge odilatador compound," as used here, refers to the elder that causes vasodilation, increases the strain to the parts of the body, increases the > Nitrous oxide, general heat or creates sensation increases sexual arousal, response or sexual dysfunction. Such substances are readily soluble in the skin and should not react adversely with any of the other ingredients and / or films used in some present mode. The modalities of this
The pharmaceutical name of alprostad is the testosterone.
Other modalities may include compue in vasodilator effects including nina nina, ginger, menthol, menthyl lactate and menthol precursors, compounds such as a, peppermint and other peppermint oils, nitric oxide uridors; that is, trinit erilo (nitroglycerin), organic nitrites; and amyl amyloid, isoamyl nitrite and similar preparations thereof, while others movate other vasodilators known in art.
In some embodiments, the elastomer layer of natural rubber latex, polyisoprene sila, polyurethane, copolymers or combinations thereof. The term "natural rubber latex" as used
ethical or natural. The natural waxes that are poured, generally, include montana, carnauba, a, barberry-myrtle, candelilla, caranday, senr no, esparto, wax from Japan, ouricury, retamo-cer residual paraffin, spermaceti, lina cane. Synthetic waxes include ethylene gene and modified polyethylenes, modified polypropylenes and base materials, and the melting point is greater than the range of 25 ° is can be melted and one or low melting can be added, such as polyethylene glycol with low and It is suitable and with the melting point, to the wax to form a solution to produce a wax with a melting point of 25 ° C to 40 ° C.
The account may include polyethylene gly
Rotation from 25 ° C to 40 ° C (or even 36-39 ° C). A PEG i PEG 1000, which has a melting point of 38 ° C for the localized incorporation of ingots of the present invention. A ba ethylene glycol wax containing PEG-6 and PEG-32, which molecular in the range of 470-530 g / mol, should be adequate. With the account that contains PEG, s when coming into contact with the generated humidity, heating occurs due to a thermal heat in the order of an increase in temperature 5-7 ° C. The effect of heating to enlarge the pores of the skin and increase the active ingredient.
One or more modalities establish that the top of the condom contains a lubricant. This l contain silicone or any other material l
based on PEG. This lubricant can contain substances that increase sexual experience to relieve symptoms associated with dysfunction. Such materials include, but are not limited to; menthol, menthyl lactate and other menthol der ureters; a compound of prostaglandi taglandin E-I, which is known under the alprostadil medicine. Another possible additive is an astringent such as witch hazel (bird a).
One or more modalities establish that the top of the condom also contains a lubricant e of the active agent. This lubricant can with or any other lubricating material atible and immiscible with the wax bead. Orient a lubricant on the outer surface,
or suitable fusion, wherein the count is the inner surface of the elastomeric layer in a condom and wherein the outer surface of the thyroid is substantially free of nonoxynol-9
In one or more modalities, the non-side account in the same is present in a quantity range of 10 to approximately 100 mg. The count can be up to 1 gram or more. It may be to orient the active ingredient in a quantity ranging from 1 to 11 2 the necessary dose, more than one ees or more of the required dose, which is the can xinol-9 generally necessary in a lubricant b con or based on water.
Additional aspects provide the methods for billing a condom, methods that include 1 melting a wax with low melting point; me
condom; and pack the condom.
Additional aspects include the method of ordering a spermicide at the closed end, the methods comprising providing a coder an elastomeric layer and a low melting o account comprising nonoxynol-9 mixture a, the count comprises a polymer modified natural wax polyethylene glycol with suitable molecular weight, where the count is the inner surface of the elastomeric layer in a condom and where the outer surface of the thyroid is substantially free of nonoxynol-9
Additional modalities of this present a package that contains the condom, as is another mode here. Examples of packaging including packaging, wraps, boxes, containers that have
The ripple of the present invention includes the finished ripple passage. Specifically, in some mod formed elastomeric layer that has the m edient placed on it is packed in an e, sealed lock container or any combination thereof. In some personifications, those m ized in the package formation are selected that can form packages that are substantially impervious to air passage and packaging materials include, but are not limited to, cellulose, such as paper or cardboard; polymeric films; metal sheets; and materi bears formed from two or more dials. The packages can be sealed to those adhesion that include, but not limited to, SYS, heat, ultrasonic welding, pre
Exemplary copies may be present in large or smaller c in one or more surfaces for particular applications and are the following.
Example IA
A modified natural wax and pol ethylene glycol wax with an appropriate molecular weight is melted until it is waxed at an os (~ 1 - 10 ° C) above the melting point, adding 100 mg of liquid nonoxynol-9. pa mix. A count of the mixture is dropped into a condom on the inside surface and it is left at room temperature and solidified. It is packed. Nonoxynol-9 can be dosed% of the weight of the wax. The use of the nonoxynol-9 concentrate can lead to the segrega xinol-9 within the wax account resulting in
Use, to which 20% of nonoxynol-9 was added to form a mixture of homogenized wax without counting the mixture is dropped at the tip of the inner surface and allowed to ambient environment and solidify.
Example II
A modified natural wax and pol ethylene glycol wax with the appropriate fusion weight formulation was melted to a few degrees (~ 1 - 10 ° C) above the point at which 100 mg of nitro is added. gone to form a mixture. An account of the m falling on the tip of a condom on the surface is allowed to cool to ambient temperature. Then the condom is packed.
Example IIIA
on is packed. A 1 count of wax of 1 gra ener 5% of niacin equivalent to 50 mg of niacin
Example IIIB
A polymer wax of polyethylene glycol glycerin and a content of 0.25% by weight, to which were added 20 mg oily soluble finely pulverized to form a counting of the mixture is dropped at the tip of the inner surface and is allowed in environment eratura and solidify. The test was carried out with 2% or 20 mg of niacin incorporated into the wax showing effective performance.
Example IV
A modified natural wax and pol ethylene glycol wax with the appropriate molecular weight melt formulation was melted to carry
enafilo.
Example V
A mixture of polymer waxes of p ol with melting points and molecular weights approached until waxing a few degrees (~ 1 above the melting point, moment in the ionan 10 -100 mg of benzocaine pulverized by mixing. Count the mixture by dropping it into a condom on the inner surface and let it rise at room temperature.
Example VI
A raw material containing a mixture olietilen glycol, PEG-ß and PEG-32 are sold from the Lanogen 1500 product by Clariant, wax is fired a few degrees (~ 1-10 ° C) by a
Example VII
A product containing a mixture of ethylene glycol, PEG-6 and PEG-32 are sold with the Lanogen 1500 product by Clariant, has been fused to a few degrees (~ 1-10 ° C) above the top, to which they added 1-3% by weight of n-ethyl and 2-5% by weight of menthol lactate for f 1a. A count of the mixture of 0.5 to 2 grams at the tip of a condom on the interst surface allowed cooling to reach the silicone ceite temperature was applied to the outer surface in an amount in the range of 0.2 to 1 gram.
The reference through this specific mode "," certain modalities "," one lities "or" one modality "means that particular character, structure, mate
convenient way in one or more modalities
Although the invention herein has been disclosed to particular embodiments, it is understood that these embodiments are only the principles and applications of the present and apparent to those skilled in the art that various modifications and variations have been made to the scope of the present invention without departing from of the ee of the invention. Thus, it is intended that the provision includes modifications and variations of the scope of the appended claims.
Claims (1)
- NOVELTY OF THE INVENTION Having described the present invention, it is considered and therefore the following is claimed as property: CLAIMS 1. A condom comprising: an elasto layer of melting point wax under which an active ingredient mixed therein, the face of which is located on the elastomeric surface at the tip of the condom. 2. The condom in accordance with the characterization because the account softens in corporal pres- sure thus exposing active substance. 5. The condom in accordance with the description characterized in that the inner surface of the thérèrica also comprises a lubricant which is miscible with the wax count of melting point 6. The condom in accordance with the reivi characterized because the active ingredient dilator. 7. The condom in accordance with the reivi characterized because the vasodilator bought niacin. 8. The condom according to the reivi characterized in that the vasodilator is composed of sildenafil citrate. 9. The condom in accordance with the reivi characterized because the account has a point of ntervalo of 25-40 ° C. 11. The condom according to claim 1 characterized in that the count comprises one polyethylene glycol numbers having a weight l in the range of 600 to 1500 and having an ion in the range of 25 ° C to 40 ° C. 12. The condom in accordance with the reivi characterized by the elastomer layer x natural rubber, synthetic polyisoprene, urethane, copolymers thereof or combination. 13. The condom according to the claim characterized in that the lubricant in the upper elastomeric layer further comprises an ingredient selected from the group consisting of ginine, a compound, of menthol, a tag tagin and an astringent. elastomeric at the tip of the condom and on the outer surface of the elastomer layer substantially free of the erectomonic ingredient rmicide and the desensitizing compound. 15. The condom conforms to the reivi characterized in that the wax erectonic ingredient is a niacin compound which is in the range of 1 - 3% by weight. 16. The condom according to the reivi characterized in that the wax erectógeno ingredient is sildenafil citrate and this pre-quantity in the range of 10 to approximately 17. The condom according to the reivi characterized in that it comprises an atible and immiscible lubricant with the account in the s 20. A method for manufacturing a coop characterized in that they comprise the steps of low melting point wax; mix a VO in the form of a liquid or as a water soluble dispersion with the low point wax d form a uniform mixture to control the condom; drop an account of the inner surface and the tip of the condom; per account reach the ambient temperature and be alone when the count is located on the surface of the condom; and pack the condom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4894608P | 2008-04-29 | 2008-04-29 | |
| US12/427,061 US20100263675A1 (en) | 2009-04-21 | 2009-04-21 | Condom with Localized Active Agent |
| PCT/US2009/041930 WO2009134767A1 (en) | 2008-04-29 | 2009-04-28 | Condom with localized active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010011780A true MX2010011780A (en) | 2010-12-17 |
Family
ID=41255377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010011780A MX2010011780A (en) | 2008-04-29 | 2009-04-28 | Condom with localized active agent. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2280674A1 (en) |
| JP (1) | JP2011518646A (en) |
| KR (1) | KR20100134782A (en) |
| CN (1) | CN102083395A (en) |
| AR (1) | AR071233A1 (en) |
| AU (1) | AU2009241580A1 (en) |
| BR (1) | BRPI0911573A2 (en) |
| CA (1) | CA2725428A1 (en) |
| IL (1) | IL209029A0 (en) |
| MX (1) | MX2010011780A (en) |
| RU (1) | RU2010148432A (en) |
| WO (1) | WO2009134767A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161617A (en) * | 2014-08-29 | 2014-11-26 | 蔺莹莹 | Novel condom and preparation method thereof |
| CN104921862B (en) * | 2015-05-25 | 2018-03-27 | 广州朗圣药业有限公司 | Measured lubrication sheath |
| US20160374849A1 (en) * | 2015-06-24 | 2016-12-29 | Ansell Limited | Packaged silicone lubricated condom that provides sensation |
| US10842664B2 (en) | 2015-10-29 | 2020-11-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Skin-like condoms having active ingredients to enhance a male erection and a female arousal |
| KR102161121B1 (en) * | 2018-11-28 | 2020-09-29 | 이성준 | Condom set with lubricant capsule |
| CN110123511B (en) * | 2019-04-30 | 2021-05-28 | 广州万方健医药有限公司 | A non-slip condom |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415188C (en) * | 2001-03-30 | 2008-09-03 | 富图拉医药发展有限公司 | Condoms containing compositions that induce an erection |
| GB0208704D0 (en) * | 2002-04-16 | 2002-05-29 | Futura Medical Dev Ltd | Condom |
| WO2004071437A2 (en) * | 2003-02-07 | 2004-08-26 | Barmensen, Inc. | Compositions for enhancing sexual responsiveness |
| US20050182076A1 (en) * | 2004-02-13 | 2005-08-18 | Adam A. Pachelo (Ano) Tina Weiss | Transdermal penetration system and treatment for cellulite |
| WO2006138428A2 (en) * | 2005-06-15 | 2006-12-28 | Hydra Biosciences, Inc. | Modulators of sperm hypermotility and uses thereof |
-
2009
- 2009-04-28 AU AU2009241580A patent/AU2009241580A1/en not_active Abandoned
- 2009-04-28 RU RU2010148432/14A patent/RU2010148432A/en unknown
- 2009-04-28 BR BRPI0911573A patent/BRPI0911573A2/en not_active Application Discontinuation
- 2009-04-28 CN CN2009801248887A patent/CN102083395A/en active Pending
- 2009-04-28 EP EP09739569A patent/EP2280674A1/en not_active Withdrawn
- 2009-04-28 JP JP2011507572A patent/JP2011518646A/en active Pending
- 2009-04-28 KR KR1020107026233A patent/KR20100134782A/en not_active Withdrawn
- 2009-04-28 WO PCT/US2009/041930 patent/WO2009134767A1/en not_active Ceased
- 2009-04-28 CA CA2725428A patent/CA2725428A1/en not_active Abandoned
- 2009-04-28 MX MX2010011780A patent/MX2010011780A/en not_active Application Discontinuation
- 2009-04-29 AR ARP090101547A patent/AR071233A1/en unknown
-
2010
- 2010-10-31 IL IL209029A patent/IL209029A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100134782A (en) | 2010-12-23 |
| CN102083395A (en) | 2011-06-01 |
| AU2009241580A1 (en) | 2009-11-05 |
| AR071233A1 (en) | 2010-06-02 |
| IL209029A0 (en) | 2011-01-31 |
| RU2010148432A (en) | 2012-06-10 |
| BRPI0911573A2 (en) | 2016-01-05 |
| EP2280674A1 (en) | 2011-02-09 |
| WO2009134767A1 (en) | 2009-11-05 |
| CA2725428A1 (en) | 2009-11-05 |
| JP2011518646A (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010011780A (en) | Condom with localized active agent. | |
| CA2422356C (en) | Suppository of retaining in lower region of rectum | |
| CA1138775A (en) | Suspension composition of benzocaine | |
| EP0173293B1 (en) | Hot melt antihistamine formulations | |
| US20100263675A1 (en) | Condom with Localized Active Agent | |
| CZ110298A3 (en) | Active substance delivery system | |
| JPH02104517A (en) | Long-lasting evacuation suppository composition and method of use | |
| EP0103995B1 (en) | Medicated suppository | |
| KR0168059B1 (en) | Liquid pesticide concentrates | |
| JP6374383B2 (en) | Transdermal preparation containing COX inhibitor | |
| TW201249475A (en) | Oily solid cosmetic composition | |
| US3776001A (en) | Self-lubricating compound for use in hygienic and medical applications, and suppositories made therefrom | |
| KR20170110204A (en) | Temperature-sensitive composite and producing method thereof | |
| CA2598588A1 (en) | Thickened spreadable warming lubricant | |
| WO1999006031A1 (en) | Pharmaceutical formulation for camptothecin analogues in gelatin capsule | |
| JP2012102083A (en) | Skin disease therapeutic agent | |
| US3927196A (en) | Soluble capsules | |
| JPWO2014171507A1 (en) | Emulsified composition | |
| NZ328180A (en) | Medicament comprising polyalkylene glycol and antiflatulent | |
| CN109908204A (en) | A kind of essential wind oil and its preparation process | |
| RU2002120505A (en) | DISPOSABLE ANTISEPTIC TAMPON AND METHOD FOR ITS MANUFACTURE | |
| DK169566B1 (en) | Liquid pharmaceutical composition containing a 4-aroyl-imidazol-2-one for use in dosage forms for oral administration and method of preparation of the composition | |
| US3072537A (en) | Surgical lubricating cream | |
| JP4242591B2 (en) | Single-use preparation for wound treatment | |
| SE453724B (en) | Skin care prepn. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |